Pharsight Corp

Pharsight — Q2 2007 Earnings Presentation

33 slides from Pharsight's earnings presentation, Nov 30, 2006

  1. Slide 1: Pharsight Corporation Investor Presentation 2nd Quarter Fiscal 2007 Update

    Slide 1: Pharsight Corporation Investor Presentation 2nd Quarter Fiscal 2007 Update

    Pharsight Corporation Investor Presentation 2nd Quarter Fiscal 2007 Update September 30, 2006 Shawn O’Connor President, Chairman and CEO Will Frederick CFO Exhibit 99.1 Confidential © Pharsight Corporation

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements, including statements regarding our financial model, growth opportunities and strategic investments, our market position, the demand and market opportunity for our products and services, financial and product performanc

  3. Slide 3: Management Team

    Slide 3: Management Team

    Management Team Shawn M. O’Connor President, Chairman and Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick Will Frederick Chief Financial Officer Versata, Clarent, ACT Networks, Disney James Hayden SVP Global Sales Accelrys, Bio-Rad Laboratories, Raytheon Mark Hovde SVP Marketing Hovd

  4. Slide 4: Market Opportunity

    Slide 4: Market Opportunity

    Market Opportunity High throughput screening Combinatorial chemistry Genomics Rational drug design nificant Productivity Increase and Investment en Geapenieed: ‘smal Pharsight Long, risky and complex process Of 5,000 screened compounds: 250 enter preclinical testing, 5 enter clinical testing and 1 i

  5. Slide 5: Market Opportunity: Product Diversification

    Slide 5: Market Opportunity: Product Diversification

    Market Opportunity Product Diversification • Customers “crossing the chasm” to full use of the Pharsight family of products can create increases of 60x in initial revenue and 15x in ongoing revenue WinNonlin Licenses Before Diversification 4 WNL Pro Users $6K $360K 0 1 2 3 4 5 6 7 8 WNL Enterprise W

  6. Slide 6: FDA Influence

    Slide 6: FDA Influence

    FDA Influence FDA and Pharsight sign CRADA - June 2006 • Pharsight will make available a comprehensive suite of software tools, including: Pharsight ® Knowledgebase Server™ (PKS™), PKS Validation Suite™, WinNonlin ® Validation Suite™, Trial Simulator™ and Drug Model Explorer™ (DMX™). • FDA will use

  7. Slide 7: Software Products

    Slide 7: Software Products

    Software Products Confidential © Pharsight Corporation

  8. Slide 8: Key Software Offerings

    Slide 8: Key Software Offerings

    Key Software Offerings • Analytics – WinNonlin ® – WinNonMix ® – Trial Simulator™ – IVIVC Toolkit™ for WinNonlin • Data Management & Compliance – Pharsight ® Knowledgebase Server™ – PKS Reporter – WinNonlin AutoPilot™ • Validation – WinNonlin Validation Suite™ – PKS Validation Suite™ • Model Visuali

  9. Slide 9: Key Software Offerings: WinNonlin

    Slide 9: Key Software Offerings: WinNonlin

    Key Software Offerings Pharsight Industry Gold-Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling, and Non Compartmental Analysis Key Benefits — Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submissions - Incr

  10. Slide 10: Key Software Offerings: WinNonMix

    Slide 10: Key Software Offerings: WinNonMix

    Key Software Offerings Pharsight Nonlinear Mixed Effects (Population) Analysis Software Application * Key Benefits - Extensive built-in library of PK, PD and PK-PD models - NONMEM data import wizard - Built-in report-ready graphics capability - Estimation algorithms for sparse and for rich data sets

  11. Slide 11: Key Software Offerings: Trial Simulator

    Slide 11: Key Software Offerings: Trial Simulator

    Key Software Offerings Pharsight State-of-the-Art Clinical Trial Design and Simulation Software * Key Benefits — Minimize risk of trial design - Formalize assumptions = Quantify uncertainty - Reduce cost of clinical trials and drug development time-to-market * Potential Growth Drivers - Increase pot

  12. Slide 12: Key Software Offerings: Pharsight Knowledgebase Server

    Slide 12: Key Software Offerings: Pharsight Knowledgebase Server

    Key Software Offerings Pharsight ® Knowledgebase Server™ (“PKS™”) • Key Benefits – Dramatically improves data management and data access – Increases productivity in analysis and reporting tasks – Supports compliance with FDA requirements for electronic records and signature, CFR 21 part 11 • Potenti

  13. Slide 13: Key Software Offerings: Drug Model Explorer

    Slide 13: Key Software Offerings: Drug Model Explorer

    Key Software Offerings Drug Model Explorer™ (“DMX ® ”) • Key Benefits – Facilitates more efficient collaboration within project teams to explore key drug attributes, and their respective uncertainties – Enables more flexible scenarios and generates views of program data from underlying model outputs

  14. Slide 14: Return on Investment Example

    Slide 14: Return on Investment Example

    Return on Investment Example “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to issue final reports decrea

  15. Slide 15: Software Products Customers

    Slide 15: Software Products Customers

    Software Products Pharsight * Over 1,200 active software customers ¢ All Top 50 Pharma? license at least one of our software products ¢ Our software applications are licensed for use on more than 6,000 desktops in industry and academia * 12 of the Top 50 Pharma? are PKS™ customers - 18 total PKS™ cu

  16. Slide 16: Strategic Consulting Services

    Slide 16: Strategic Consulting Services

    Strategic Consulting Services Confidential © Pharsight Corporation

  17. Slide 17: Strategic Consulting Services

    Slide 17: Strategic Consulting Services

    Strategic Consulting Services Formal, quantitative, model-based decision-making method Increases drug development productivity Decreases late stage attrition Decreases time-to-market Reduces financial investment Improves clinical quality and commercial performance of final product

  18. Slide 18: Quantitative Modeling Supports Both Trial- and Program-Level Decisions

    Slide 18: Quantitative Modeling Supports Both Trial- and Program-Level Decisions

    Quantitative Modeling Supports Both Trial- and Program-Level Decisions Animal PK Data Human PK Data Treatment, Exposure Patient Endpoints Trial Outcomes Market Acceptance Drug and Patient Models Trial Models Market Models • Optimize treatment regimens and patient populations for the market and for a

  19. Slide 19: Overview of Consulting Services

    Slide 19: Overview of Consulting Services

    Overview of Consulting Services • World-class experts in clinical pharmacology, PK/PD, decision analysis, and statistics • Senior scientific leadership with extensive drug development experience • Seasoned practitioners from industry, academia, and consulting • Serving all major drug development geo

  20. Slide 20: Strategic Consulting Services: Revenue Diversification

    Slide 20: Strategic Consulting Services: Revenue Diversification

    Strategic Consulting Services Revenue Diversification Q2 FY07 50% 50% Top 2 clients Others Q2 FY06 81% 19% Top 2 clients Others $2.7M Revenue $1.9M Revenue Successful Diversification Efforts with Reduced Revenue Dependency on “Top 2 Clients”

  21. Slide 21: Return on Investment Example

    Slide 21: Return on Investment Example

    Return on Investment Example Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound. The ratio between the therapeutic benefit a

  22. Slide 22: Financial Overview

    Slide 22: Financial Overview

    Financial Overview Confidential © Pharsight Corporation

  23. Slide 23: Accomplishments and Guidance

    Slide 23: Accomplishments and Guidance

    Accomplishments and Guidance FY06 Accomplishments • Revenue growth – Y/Y revenue growth of 1% – consecutive year of revenue growth • Gross Margin – 66% of revenue • Profitability – Net income of $530,000 – consecutive year of profitability • Achieved positive annual net cash flow FY07 Guidance • Con

  24. Slide 24: Summary Income Statements

    Slide 24: Summary Income Statements

    Summary Income Statements (in thousands) Consol. SPBU SCS Consol. SPBU SCS Revenue 6,284 3,553 2,731 5,920 4,005 1,915 Y/Y growth 6% -11% 43% 17% 60% -25% Cost of revenue 1,817 1,464 2,054 1,390 Gross profit 4,467 3,200 1,267 3,866 3,341 Gross margin 71% 90% 46% 65% 83% 27% Operating expenses 3,753

  25. Slide 25: Summary Balance Sheets

    Slide 25: Summary Balance Sheets

    Summary Balance Sheets (in thousands) Sep. 30, March 31, Cash & cash equivalents 6,438 $ 10,832 $ Short-term investments 4,749 -- Accounts receivable, net 3,397 4,585 Total current assets 15,170 15,715 Total assets 16,998 $ 17,786 $ LIABILITIES & STOCKHOLDERS' DEFICIT A/P & accrued expenses 3,612 $

  26. Slide 26: Annual Revenue by Business Unit

    Slide 26: Annual Revenue by Business Unit

    Annual Revenue by Business Unit (in thousands) $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 FY03 FY04 FY05 FY06 FY07 Guidance Software Products Strategic Consulting Guidance ($25M - $26M)

  27. Slide 27: Quarterly Revenue by Business Unit

    Slide 27: Quarterly Revenue by Business Unit

    Quarterly Revenue by Business Unit (in thousands) $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 Q2 FY06 Q3 FY06 Q4 FY06 Q1 FY07 Q2 FY07 Software Products Strategic Consulting

  28. Slide 28: Annual Gross Profit

    Slide 28: Annual Gross Profit

    Annual Gross Profit (in thousands) $0 $2,500 $5,000 $7,500 $10,000 $12,500 $15,000 $17,500 FY02 FY03 FY04 FY05 FY06

  29. Slide 29: Annual Operating Income

    Slide 29: Annual Operating Income

    Annual Operating Income (in thousands) -$20,000 -$17,500 -$15,000 -$12,500 -$10,000 -$7,500 -$5,000 -$2,500 $0 $2,500 $5,000 FY02 FY03 FY04 FY05 FY06

  30. Slide 30: Annual Operating Cash Flow

    Slide 30: Annual Operating Cash Flow

    Annual Operating Cash Flow (in thousands) -$8,000 -$6,000 -$4,000 -$2,000 $0 $2,000 $4,000 FY02 FY03 FY04 FY05 FY06

  31. Slide 31: Pharsight

    Slide 31: Pharsight

    Pharsight

  32. Slide 32: Proprietary Notice

    Slide 32: Proprietary Notice

    Proprietary Notice Pharsight All contents Copyright ©2006 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocop

  33. Slide 33: Pharsight

    Slide 33: Pharsight

Source: SEC EDGAR · 8-K filed Nov 30, 2006

More decks from Pharsight Corp